STOCK TITAN

Surmodics Inc Stock Price, News & Analysis

SRDX Nasdaq

Welcome to our dedicated page for Surmodics news (Ticker: SRDX), a resource for investors and traders seeking the latest updates and insights on Surmodics stock.

Surmodics Inc. (SRDX) drives innovation in medical device coatings and diagnostic solutions through partnerships with global healthcare leaders. This news center delivers verified updates on the company's financial developments, regulatory milestones, and technological breakthroughs shaping patient care.

Find curated press releases detailing SRDX's advancements in vascular intervention systems, diagnostic platform enhancements, and strategic collaborations. Track earnings reports and product launch announcements that highlight the company's transition from coating pioneer to comprehensive medical solution developer.

Our repository includes updates on FDA clearances, clinical study results, and manufacturing expansions critical for assessing SRDX's market position. Discover how the company's surface modification expertise addresses challenges in drug delivery systems and in-vitro diagnostics.

Bookmark this page for ongoing insights into Surmodics' role in medical innovation. Return regularly to stay informed about developments impacting the future of minimally invasive therapies and diagnostic accuracy.

Rhea-AI Summary

Surmodics (SRDX) announced early results from its PROWL registry study evaluating the Pounce™ Thrombectomy System in treating limb ischemia. A subset analysis of 60 patients demonstrated 96.8% procedural flow restoration, with 81.7% requiring no additional thromboemboli removal treatment within 30 days. The study showed 90.0% procedural success and 80.8% technical success. Notably, 66.7% of patients avoided ICU admission, and 81.7% were discharged home. The study included patients with acute (60.0%), subacute (16.7%), and chronic (23.3%) limb ischemia, demonstrating effectiveness across various clot chronicity levels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
-
Rhea-AI Summary

Surmodics (Nasdaq: SRDX) has received FDA 510(k) clearance for its Pounce™ XL Thrombectomy System, expanding its Pounce Thrombectomy Platform to treat peripheral arteries up to 10 mm in diameter. This new system is designed for non-surgical removal of thrombi and emboli in vessels 5.5–10 mm, including iliac and femoral arteries. The Pounce Thrombectomy Platform already includes systems for 2–6 mm arteries. The Pounce XL aims to address critically ischemic lower extremity vessels, providing a rapid solution for various clot morphologies without thrombolytics. market release is expected in early 2025, followed by full commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
-
Rhea-AI Summary

Surmodics (Nasdaq: SRDX) reported Q3 FY2024 financial results. Total revenue was $30.3M, down 42% from $52.5M in the prior-year period, which included a $24.6M license fee upon FDA approval of SurVeil™ DCB. Excluding this, revenue increased 10% YoY to $29.2M. GAAP net loss was $(7.6)M, compared to net income of $7.3M last year. Adjusted EBITDA was $1.6M, down from $24.6M.

Medical Device revenue fell 49% to $23.4M but grew 10% YoY excluding the SurVeil DCB fee. In Vitro Diagnostics revenue rose 8% to $7.0M. Gross profit increased 4% to $9.1M, with margins declining to 51.9% from 55.8%. Operating costs rose 13% to $27.3M due to merger-related charges.

The company is being acquired by GTCR for $43/share, with a shareholder vote on August 13, 2024. Surmodics also secured a new agreement with Premier for thrombectomy products. FY2024 guidance is suspended due to the pending acquisition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
Rhea-AI Summary

Surmodics (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies, has secured a group purchasing agreement for thrombectomy products with Premier. Effective June 1, 2024, this agreement allows Premier members to access special pricing and terms for Surmodics' Pounce™ and Pounce™ Venous Thrombectomy Systems. These systems, which remove arterial and venous clots without the need for capital equipment, aim to enhance procedural efficiency and reduce the necessity for thrombolytic drugs. The partnership with Premier, which includes 4,350 U.S. hospitals and 300,000 other providers, is expected to expand Surmodics' market reach and support high-quality, cost-effective care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
Rhea-AI Summary

Surmodics, a healthcare technology provider, has agreed to be acquired by GTCR, a private equity firm, for $43.00 per share in cash, valuing the company at approximately $627 million. The acquisition price offers a 41.1% premium over Surmodics' 30-day average closing price through May 28, 2024. The deal, approved unanimously by Surmodics' Board of Directors, is expected to close in the second half of 2024, subject to shareholder and regulatory approval. Following the acquisition, Surmodics will become privately held and delist from Nasdaq. The transaction will be financed through GTCR's equity and debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.94%
Tags
-
Rhea-AI Summary

Surmodics, Inc. (Nasdaq: SRDX) reported Q2 FY 2024 results with total revenue of $32.0 million, a 18% increase YoY, excluding SurVeil™ DCB license fee revenue. GAAP net income was $0.2 million. The company launched two new thrombectomy devices, the Pounce™ Venous and Pounce LP, for venous and arterial vasculatures. Surmodics increased revenue and EPS guidance for FY 2024 due to strong performance and product launches, expecting $122-124 million in total revenue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.74%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.9%
Tags

FAQ

What is the current stock price of Surmodics (SRDX)?

The current stock price of Surmodics (SRDX) is $27.99 as of October 18, 2025.

What is the market cap of Surmodics (SRDX)?

The market cap of Surmodics (SRDX) is approximately 400.3M.
Surmodics Inc

Nasdaq:SRDX

SRDX Rankings

SRDX Stock Data

400.33M
13.74M
3.4%
90.81%
2.7%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
EDEN PRAIRIE